From MarketBeat:



Ariel Hurley, an insider in Blueprint Medicines Co., has sold 714 shares of the company’s stock at an average price of $90.00, totaling to $64,260.0. Immediately after the sale, Hurley now directly owns 14,324 shares in the company, valued at approximately $1,289,160. Blueprint Medicines Co.’s stock is showing an upward trend with a 50-day moving average price of $66.62 and a 200-day moving average price of $58.76. The company has a market cap of $5.52 billion, a PE ratio of -9.89 and beta of 0.68.

The company recently released its quarterly earnings report, showing a negative net margin of 256.57% and a negative return on equity of 153.79%. Despite this, several equity analysts, such as Wells Fargo & Company and StockNews.com, have weighed in on the stock, giving a “buy” rating. Blueprint Medicines Corp. is focused on developing precision therapy for genomically defined cancers and blood disorders in the United States and internationally.

Additionally, various hedge funds and institutional investors have shown interest in Blueprint Medicines, including the Bessemer Group Inc., Granahan Investment Management LLC, and more, showing growth potential for the company.



Read more: Insider Selling: Blueprint Medicines Co. (NASDAQ:BPMC) Insider Sells 714 Shares of Stock